Market revenue in 2024 | USD 204.8 million |
Market revenue in 2030 | USD 121.2 million |
Growth rate | -8.9% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Beovu |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 46.34% in 2024. Horizon Databook has segmented the Japan anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s anti-VEGF therapeutics market is anticipated to witness lucrative growth over the forecast period due to strategic initiatives undertaken by companies to introduce novel treatments, coupled with favorable government initiatives that promote the adoption of such products through reimbursement coverage.
In May 2020, Novartis AG introduced the novel anti-VEGF inhibitor Beovu (brolucizumab) for the treatment of AMD in Japan. The introduction of a new product may increase market growth in the country.
In addition, DAIICHI SANKYO COMPANY, LIMITED launched the biosimilar of Avastin (bevacizumab) with 100 mg and 400 mg intravenous drip infusions. This product can be used as an off-label drug for AMD. The product was introduced in December 2019, and in November 2019, the product was listed in NHI reimbursement.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Japan anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account